Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adaltis Appoints Executive Vice President/CFO
Gardner graduated from Concordia University and is a Certified General Accountant. “As we head into an accelerated period of growth with the launch of EclecticaTM and the growing
Gardner graduated from Concordia University and is a Certified General Accountant. “As we head into an accelerated period of growth with the launch of EclecticaTM and the growing
Xtent, a medical device company, has received CE Mark approval for its Custom NX drug-eluting stent system. The CE Mark indicates that the Custom NX drug-eluting stent (DES)
Champions Biotechnology has reported a net loss of $623,234, or $0.02 per basic share, for the third quarter of fiscal 2009, compared to a net income of $311,006,
Primary endpoints were met in all of the clinical programs required for the submission of the new drug application (NDA), comprising a long-term safety study and four efficacy
Pursuant to the terms of the agreement, MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement,
For the year ended December 31, 2008, the company reported a net loss of RMB52.3 million, or RMB0.39 per share, compared to a net income of RMB165.65 million,
According to the report, the Chinese health authorities investigated 33 products, including baby shampoo, made by Johnson & Johnson (J&J) after a US consumer group alleged that the
NeoStem, a developer of adult stem cell collection centers, has signed an agreement with Vincent Giampapa to open a new stem cell collection center at the Giampapa Institute
For the year ended December 31, 2008, the company reported a net loss of C$1.54 million, compared to a net loss of C$1.35 million for the year ended
The sale of the shares was achieved partly through market sales under Rule 144 of the US Securities Act of 1933, and, partly through a sale directly to